You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Diffuse%20large%20B-cell%20lymphoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

High-Dose Methotrexate Clearance in Diffuse Large B-Cell

Recruiting
  • Central Nervous System Lymphoma
  • Diffuse Large B-Cell Lymphoma
  • Non-Interventional Study
  • Columbus, Ohio
    Ohio State University Comprehensive Cancer Center
Sep 8, 2023

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Diffuse Large B Cell Lymphoma | DLBCL Recurrent/Refractory Trial (ZR2-ICE)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma | Diffuse Large B-Cell Lymphoma Recurrent/Refractory
  • (no location specified)
Sep 5, 2023

Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory Trial in Hangzhou (Anlotinib HCl, Rituximab,

Recruiting
  • Diffuse Large B-cell Lymphoma Recurrent
  • Diffuse Large B Cell Lymphoma Refractory
  • Anlotinib hydrochloride, Rituximab, gemcitabine, oxaliplatin
  • Hangzhou, Zhejiang, China
    Zhejiang Cancer Hospital
Oct 12, 2023

Relapsed or Refractory Diffuse Large B-cell Lymphoma Trial in Beijing (BEBT-908 for injection)

Active, not recruiting
  • Relapsed or Refractory Diffuse Large B-cell Lymphoma
  • BEBT-908 for injection
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Oct 8, 2023

DLBCL Trial (Polatuzumab Vedotin)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Polatuzumab Vedotin
  • (no location specified)
Jul 12, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab vedotin and Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab vedotin and Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

Diffuse Large B Cell Lymphoma Trial in Shanghai (Zanubrutinib, Polatuzumab Vedotin, Rituximab)

Recruiting
  • Diffuse Large B Cell Lymphoma
  • Zanubrutinib, Polatuzumab Vedotin, Rituximab
  • Shanghai, Shanghai, China
    Zhongshan Hospital，Fudan University
Jul 10, 2023

DLBCL Trial in Jinan (Mitoxantrone Hydrochloride Liposome Injection)

Not yet recruiting
  • Diffuse Large B-Cell Lymphoma
  • Mitoxantrone Hydrochloride Liposome Injection
  • Jinan, Shandong, China
    Affiliated Cancer Hospital of Shandong First Medical University
May 16, 2023

Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Cyclophosphamide)

Not yet recruiting
  • Diffuse Large B-cell Lymphoma
  • (no location specified)
Mar 9, 2023

Diffuse Large B Cell Lymphoma Trial in Rouen (Measure of the circulating tumor DNA)

Not yet recruiting
  • Diffuse Large B Cell Lymphoma
  • Measure of the circulating tumor DNA
  • Rouen, France
    Centre Henri Becquerel
Nov 17, 2023

Costs of CAR-T Therapies in Diffuse Large B-cell Lymphoma:

Completed
  • Diffuse Large B-cell Lymphoma
    • East Hanover, New Jersey
      Novartis
    Jun 16, 2023

    DLBCL Trial (Acalabrutinib, Rituximab)

    Not yet recruiting
    • Diffuse Large B-Cell Lymphoma
    • (no location specified)
    Jul 11, 2023

    Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

    Not yet recruiting
    • Lymphoma, B-Cell
    • +6 more
    • Plasma metabolomic profile by Ultra-high performance liquid chromatography with quadrupole time-of-flight mass spectrometry (UPLC-QTOFMS)
    • Guayaquil, Guayas, Ecuador
      Instituto Oncológico Nacional Dr. Juan Tanca Marengo
    Apr 27, 2023

    Diffuse Large B-cell Lymphoma Trial (Rituximab, Mitoxantrone HCl liposome, Isophosphamide)

    Not yet recruiting
    • Diffuse Large B-cell Lymphoma
    • (no location specified)
    Mar 23, 2023

    Selinexor Combined With Lenalidomide and Rituximab in Treatment

    Not yet recruiting
    • Lymphoma, Large B-Cell, Diffuse
    • Selinexor combined with lenalidomide and rituximab
    • Shanghai, China
      Ruijin Hospital, Shanghai Jiao Tong University School of Medicin
    Jun 20, 2023

    Frontline of ASCT in High-risk DLBCL

    Recruiting
    • Diffuse Large B Cell Lymphoma
      • Beijing, Beijing, China
        Peking University People's Hospital
      Apr 26, 2023

      Diffuse Large B-cell Lymphoma Trial in Changchun (Mitoxantrone HCl liposome injection, RiTUXimab Injection, Cyclophosphamid)

      Not yet recruiting
      • Diffuse Large B-cell Lymphoma
      • Mitoxantrone hydrochloride liposome injection
      • +4 more
      • Changchun, Jilin, China
        The First Bethune Hospital of Jilin University
      Aug 15, 2023

      Relapsed/Refractory Diffuse Large B Cell Lymphoma Trial in Seoul (Glofitamab, Poseltinib, Lenalidomide)

      Recruiting
      • Relapsed/Refractory Diffuse Large B Cell Lymphoma
      • Glofitamab, Poseltinib, Lenalidomide
      • Seoul, Korea, Republic of
        Seoul National University Hospital
      Nov 28, 2022

      DLBCL - Diffuse Large B Cell Lymphoma, Follicular Lymphoma Trial in Xiamen (Lenalidomide combined with G-CHOP (LO CHOP))

      Recruiting
      • DLBCL - Diffuse Large B Cell Lymphoma
      • Follicular Lymphoma
      • Lenalidomide combined with G-CHOP (LO CHOP)
      • Xiamen, Fujian, China
        Bing Xu
      Nov 28, 2023

      DLBCL, High-grade B-cell Lymphoma Trial (Loncastuximab Tesirine)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • High-grade B-cell Lymphoma
      • Loncastuximab Tesirine
      • (no location specified)
      Dec 13, 2022

      DLBCL Trial (maplirpacept (PF-07901801), Glofitamab, Obinutuzumab)

      Not yet recruiting
      • Diffuse Large B-Cell Lymphoma
      • maplirpacept (PF-07901801)
      • +2 more
      • (no location specified)
      May 30, 2023

      Advanced DLBCL, Extra-nodal Involvement, Large Mass, Radiotherapy Trial (6-8 cycles (21 days per cycle) of Standard R-CHOP

      Not yet recruiting
      • Advanced Diffuse Large B-Cell Lymphoma
      • +2 more
      • 6-8 cycles (21 days per cycle) of Standard R-CHOP chemotherapy
      • Radiotherapy beyond standard R-CHOP Chemotherapy
      • (no location specified)
      May 24, 2023

      Diffuse Large B Cell Lymphoma Trial (Epcoritamab, Lenalidomide)

      Not yet recruiting
      • Diffuse Large B Cell Lymphoma
      • (no location specified)
      Jan 20, 2023

      Chidamide in Recurrent and Refractory Diffuse Large b

      Enrolling by invitation
      • Diffuse Large B-cell Lymphoma
      • Suzhou, Jiangsu, China
        Second Affiliated Hospital of Soochow University
      Jan 9, 2023